Skip to Main Content

Paper Details

Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.
Neurology
19
2021
1p/19q, 1p/19q codeleted, Grade II-IV Gliomas, IDH, IDH mutant, IDH mutation, LGG, LGGs, MGMT, MGMT promoter, O6-methylguanine, O6-methylguanine-DNA methyltransferase, Patients, VTE, Venous Thromboembolism, diffuse glioma, glioblastoma, glioma, gliomas grade II-IV, isocitrate, isocitrate dehydrogenase, lower-grade gliomas, patients, venous thromboembolism
Adult, Aged, Brain Neoplasms, Female, Glioma, Humans, Incidence, Isocitrate Dehydrogenase, Male, Middle Aged, Mutation, Neoplasm Grading, Promoter Regions, Genetic, Retrospective Studies, Risk, Venous Thromboembolism
Author NameAffiliation
Maria DiazUniversity of Virginia, Memorial Sloan Kettering Cancer Center, East Carolina University/Vidant Medical Center
Jasmin JoUniversity of Virginia, Memorial Sloan Kettering Cancer Center, East Carolina University/Vidant Medical Center
Mark E SmolkinUniversity of Virginia, Memorial Sloan Kettering Cancer Center, East Carolina University/Vidant Medical Center
Sarah J Ratcliffe (CM4AI)University of Virginia, Memorial Sloan Kettering Cancer Center, East Carolina University/Vidant Medical Center
David SchiffUniversity of Virginia, Memorial Sloan Kettering Cancer Center, East Carolina University/Vidant Medical Center
  • 1 - 5

Datasets

Release 1.2